SOPHiA GENETICS reported its financial results for the fourth quarter and full fiscal year ended December 31, 2024. Fourth-quarter revenue was $17.733 million, a 4.0% increase from $17.048 million in Q4 2023. For the full year 2024, total revenue reached $65.173 million, up 4.5% from $62.371 million in 2023.
The company's loss for the fourth quarter narrowed to $(15.158) million from $(24.060) million in Q4 2023, with basic and diluted loss per share improving to $(0.23) from $(0.37). For the full year, the loss for the period was $(62.493) million, an improvement from $(78.981) million in 2023, and basic and diluted loss per share was $(0.95) compared to $(1.22).
SOPHiA GENETICS provided its financial outlook for the full year 2025, projecting revenue between $72 million and $76 million, representing 10% to 17% growth. The adjusted EBITDA loss guidance was set at $35 million to $39 million. The company highlighted catalysts for 2025, including the MSK-ACCESS® liquid biopsy application, opportunities in the U.S. market, and a base of 92 new customers to onboard and expand.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.